Atara Biotherapeutics Inc's Comment on Supply Chain
The company's manufacturing operations for its products and product candidates are subject to potential disruptions from pandemics, natural disasters, equipment failures, labor shortages, and power outages. Supply interruptions of raw materials and consumables, including leukapheresis collections used as starting materials, have occurred due to the COVID-19 pandemic and other global factors. The production of cellular therapies involves complex processes that are vulnerable to product loss from contamination, equipment failure, or operator error. Contamination incidents, such as mold detected by a Contract Manufacturing Organization (CMO) in manufacturing suites for the Ebvallo and tab-cel products, have led to temporary halts in manufacturing activities. The company and its commercialization partner have collaborated with the CMO to investigate and resolve these issues. The FDA has confirmed that inspectional concerns at the CMO facility have been adequately addressed. The manufacturing process relies on third-party donor cells, introducing risks related to the availability of donor material. It also requires specialized equipment, skilled personnel, and maintenance of aseptic conditions over several weeks, with potential contamination risks from viruses or pathogens present in donor or manufacturing materials.
Atara Biotherapeutics Inc's Comment on Supply Chain
The company's manufacturing operations for its products and product candidates are subject to potential disruptions from pandemics, natural disasters, equipment failures, labor shortages, and power outages. Supply interruptions of raw materials and consumables, including leukapheresis collections used as starting materials, have occurred due to the COVID-19 pandemic and other global factors. The production of cellular therapies involves complex processes that are vulnerable to product loss from contamination, equipment failure, or operator error. Contamination incidents, such as mold detected by a Contract Manufacturing Organization (CMO) in manufacturing suites for the Ebvallo and tab-cel products, have led to temporary halts in manufacturing activities. The company and its commercialization partner have collaborated with the CMO to investigate and resolve these issues. The FDA has confirmed that inspectional concerns at the CMO facility have been adequately addressed. The manufacturing process relies on third-party donor cells, introducing risks related to the availability of donor material. It also requires specialized equipment, skilled personnel, and maintenance of aseptic conditions over several weeks, with potential contamination risks from viruses or pathogens present in donor or manufacturing materials.
Sources:
Atara Biotherapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Atara Biotherapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
